Amira asset DP2 blockers spun out, not part of BMS $325 million buyout
12 September 2011
Nancy Faigen
Please Login to read the full article.
12 September 2011
Nancy Faigen
nancy.faigen@informausa.com
Please Login to read the full article.
RELATED CONTENT
NEWS
- "Welcome home": Stromedix buy brings fibrosis drug back to Biogen
- ROCK on, ROCK off: Amakem gets €18 million to address rho kinase side-effect problem
- Stockwatch: Bitter-sweet biotech buy-outs
- Promedior's new $21.5M series D helps advance fibrosis portfolio, including IPF and mylelofibrosis
COMMENT
Other Informa Comment
EVENTS
Today
Le Plaza Hotel, Brussels, Belgium
Today
Diplomat Hotel, Prague, Czech Republic
Today
Business Design Centre, London
JOB OF THE WEEK
Section Head (m/f)
DRA International/CIS Section
Section Head (m/f)
DRA International/CIS Section
